CY1110430T1 - Πολυπεπτιδια περιεχοντα πολυμορφισμους των επαναλαμβανομενων περιοχων της περτακτινης σε bordetella pertussis, bordetella paraperussis kai bordetella bronchiseptica. χρηση αυτων σε διαγνωστικες και ανοσογονες συνθεσεις - Google Patents

Πολυπεπτιδια περιεχοντα πολυμορφισμους των επαναλαμβανομενων περιοχων της περτακτινης σε bordetella pertussis, bordetella paraperussis kai bordetella bronchiseptica. χρηση αυτων σε διαγνωστικες και ανοσογονες συνθεσεις

Info

Publication number
CY1110430T1
CY1110430T1 CY20081100716T CY081100716T CY1110430T1 CY 1110430 T1 CY1110430 T1 CY 1110430T1 CY 20081100716 T CY20081100716 T CY 20081100716T CY 081100716 T CY081100716 T CY 081100716T CY 1110430 T1 CY1110430 T1 CY 1110430T1
Authority
CY
Cyprus
Prior art keywords
bordetella
pertactin
repeat regions
pertussis
paraperussis
Prior art date
Application number
CY20081100716T
Other languages
English (en)
Inventor
Nicole Guiso-Maclouf
Caroline Boursaux-Eude
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of CY1110430T1 publication Critical patent/CY1110430T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η περτακτίνη (PNP) είναι μία πρωτεΐνη εξωτερικής μεβράνης που εκφράζεται από Bordetella pertussis Bordetella parapertussis και Bordetella bronchiseptica, η οποία επάγει ανοσία σε μολύνσεις από Bordetella. Οι ανοσοεπικρατείς και ανοσοπροστατευτικού επιτόποι της περτακτίνης περιλαμβάνουν δύο επαναλαμβανόμενες περιοχές Ι και ΙΙ. Σύγκριση αυτών των δύο επαναλαμβανόμενων περιοχών έδειξε ότι περτακτίνη του B. parapertussis δεν έχει παραλλαγή, ενώ η περτακτίνη του B. pertussis ποικίλει κυρίως στην περιοχή Ι. H Β. brochiseptica ποικίλει και στις δύο επαναλαμβανόμενες περιοχές Ι και ΙΙ. Συνθέσεις που περιέχουν περτακτίνες και θραύσματα περτακτίνης που περιέχουν ποικίλουσες αλληλουχίες σε αυτές τις περιοχές είναι χρήσιμες σε ανοσογόνες συνθέσεις.
CY20081100716T 2000-05-25 2008-07-08 Πολυπεπτιδια περιεχοντα πολυμορφισμους των επαναλαμβανομενων περιοχων της περτακτινης σε bordetella pertussis, bordetella paraperussis kai bordetella bronchiseptica. χρηση αυτων σε διαγνωστικες και ανοσογονες συνθεσεις CY1110430T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20696900P 2000-05-25 2000-05-25
PCT/EP2001/006457 WO2001090143A2 (en) 2000-05-25 2001-05-23 Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella parapertussis and bordetella bronchiseptica. their use in diagnostics, and in immunogenic compositions

Publications (1)

Publication Number Publication Date
CY1110430T1 true CY1110430T1 (el) 2012-05-23

Family

ID=22768696

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100716T CY1110430T1 (el) 2000-05-25 2008-07-08 Πολυπεπτιδια περιεχοντα πολυμορφισμους των επαναλαμβανομενων περιοχων της περτακτινης σε bordetella pertussis, bordetella paraperussis kai bordetella bronchiseptica. χρηση αυτων σε διαγνωστικες και ανοσογονες συνθεσεις

Country Status (11)

Country Link
US (3) US7070779B2 (el)
EP (1) EP1284993B1 (el)
JP (1) JP2003533990A (el)
AT (1) ATE393166T1 (el)
AU (1) AU2001267527A1 (el)
CY (1) CY1110430T1 (el)
DE (1) DE60133734T2 (el)
DK (1) DK1284993T3 (el)
ES (1) ES2303833T3 (el)
PT (1) PT1284993E (el)
WO (1) WO2001090143A2 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
JP2003533990A (ja) 2000-05-25 2003-11-18 インスティチュート・パスツール 百日咳菌、パラ百日咳菌および気管支敗血症菌のペルタクチンの繰返し領域の多型性を有するポリペプチド、ならびに診断および免疫原性組成物におけるその使用
US8465754B2 (en) 2007-05-28 2013-06-18 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Bordetella parapertussis whole-cell vaccine composition
CU23679A1 (es) * 2007-10-30 2011-07-11 Ct Ingenieria Genetica Biotech Variantes de pertactinas para uso vacunal
EP2430040A1 (en) * 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
US8261986B2 (en) * 2009-10-21 2012-09-11 Kevin Kwong-Tai Chung System and method for decoding an optically readable markable sheet and markable sheet therefor
DK2670432T3 (da) * 2011-02-04 2021-04-19 Zoetis Services Llc Immunogene Bordetella bronchiseptica-sammensætninger
KR20130112950A (ko) * 2011-02-04 2013-10-14 조에티스 엘엘씨 개 호흡기 복합 질환용 조성물
CN109879942A (zh) * 2019-03-01 2019-06-14 浙江省农业科学院 一种兔波氏杆菌外膜蛋白及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007416D0 (en) * 1990-04-02 1990-05-30 Wellcome Found Expression of heterologous protein in yeast
GB9027901D0 (en) * 1990-12-21 1991-02-13 Wellcome Found Acellular vaccine
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
JP2003533990A (ja) * 2000-05-25 2003-11-18 インスティチュート・パスツール 百日咳菌、パラ百日咳菌および気管支敗血症菌のペルタクチンの繰返し領域の多型性を有するポリペプチド、ならびに診断および免疫原性組成物におけるその使用

Also Published As

Publication number Publication date
EP1284993B1 (en) 2008-04-23
US20030180307A1 (en) 2003-09-25
WO2001090143A2 (en) 2001-11-29
US7314910B2 (en) 2008-01-01
ES2303833T3 (es) 2008-09-01
PT1284993E (pt) 2008-06-11
EP1284993A2 (en) 2003-02-26
DE60133734T2 (de) 2009-05-14
WO2001090143A3 (en) 2002-09-26
US20040166116A9 (en) 2004-08-26
US6964767B2 (en) 2005-11-15
US20060008474A1 (en) 2006-01-12
DK1284993T3 (da) 2008-07-28
DE60133734D1 (de) 2008-06-05
US20020192237A1 (en) 2002-12-19
AU2001267527A1 (en) 2001-12-03
US7070779B2 (en) 2006-07-04
JP2003533990A (ja) 2003-11-18
ATE393166T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
CY1110430T1 (el) Πολυπεπτιδια περιεχοντα πολυμορφισμους των επαναλαμβανομενων περιοχων της περτακτινης σε bordetella pertussis, bordetella paraperussis kai bordetella bronchiseptica. χρηση αυτων σε διαγνωστικες και ανοσογονες συνθεσεις
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
IS7593A (is) Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
EA200300503A1 (ru) Новые лекарственные композиции на основе солей тиотропия и солей салметерола
EA200201214A1 (ru) Замещенные тиоацетамиды
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
DK1261377T3 (da) Immunmodulatoriske formuleringer og fremgangsmåder til anvendelse af disse
HUP0002475A2 (hu) Módosított immunogén pneumolizinkészítmények mint vakcinák
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
ES2087109T3 (es) Procedimiento para la purificacion de una proteina antigenica de 69000 daltons a partir de bordetella pertussis.
ATE383871T1 (de) Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
DE60140972D1 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
LU90378I2 (fr) Tetravac
DK0863981T3 (da) Detektering, forebyggelse og behandling af papillomatous digital dermatitis
BR0016616A (pt) Microrganismos atenuados para o tratamento de infecção
DK1149901T3 (da) Mutanter af pestivirus og vacciner indeholdende disse
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
DK0563288T3 (da) Immunopotentiering af vacciner, navnlig svinepleuropneumoniavacciner